Medical management of pancreatic neuroendocrine tumors in patients with MEN 1: case report

被引:0
作者
Mohajeri-Tehrani, Mohammad Reza [1 ]
Ebrahimpur, Mahbube [2 ]
Nasseri-Moghaddam, Siavosh [3 ]
Tavangar, Seyed-Mohammad [4 ]
Sani, Mahnaz Pejman [1 ]
Zandi, Abdollah [5 ]
Shadmehr, Mohammad Behgam [6 ]
机构
[1] Univ Tehran Med Sci, Endocrinol & Metab Clin Sci Inst, Endocrinol & Metab Res Ctr, Tehran, Iran
[2] Univ Tehran Med Sci, Endocrinol & Metab Populat Sci Inst, Elderly Hlth Res Ctr, Tehran, Iran
[3] Univ Tehran Med Sci, Shariati Hosp, Digest Dis Res Ctr, Tehran, Iran
[4] Tehran Med Univ Med Sci, Dept Pathol, Tehran, Iran
[5] Atiyeh Hosp, Fellowship Bariatr Surg, Tehran, Iran
[6] Shahid Beheshti Univ Med Sci, Natl Res Inst TB & Lung Dis NRITLD, Tracheal Dis Res Ctr TDRC, Tehran, Iran
关键词
Multiple endocrine neoplasia; Neuroendocrine tumors; Case management; Octreotide;
D O I
10.1007/s40200-022-01067-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives Multiple endocrine neoplasia type 1 (MEN-1) is a rare inherited autosomal dominant disease which manifests itself with at least one clinical scenario before 45 years of age. The value of somatostatin analogue therapy is unknown in the treatment of non-functioning pancreatic tumours and a few studies have been published in this field. Case presentation We report a young patient with MEN-1 with multiple gastric and pancreatic neuroendocrine tumors that was treated with the monthly injection of Sandostatin LAR before and After Distal Pancreatectomy and partial gastrectomy. Conclusions Now she is well after four years of treatment with Sandostatin LAR.
引用
收藏
页码:2009 / 2011
页数:3
相关论文
共 11 条
  • [1] Multiple Endocrine Neoplasia Type 1
    Agarwal, Sunita K.
    [J]. ENDOCRINE TUMOR SYNDROMES AND THEIR GENETICS, 2013, 41 : 1 - 15
  • [2] BOLONDI L, 1990, J CLIN GASTROENTEROL, V12, P218
  • [3] Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly
    Caron, P
    Beckers, A
    Cullen, DR
    Goth, MI
    Gutt, B
    Laurberg, P
    Pico, AM
    Valimaki, M
    Zgliczynski, W
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (01) : 99 - 104
  • [4] The role of somatostatin analogues in the treatment of neuroendocrine tumours
    Grozinsky-Glasberg, Simona
    Grossman, Ashley B.
    Korbonits, Marta
    [J]. MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2008, 286 (1-2) : 238 - 250
  • [5] Endosonography of the adrenal glands: normal size - pathological findings
    Kann, P
    Hengstermann, C
    Heussel, CP
    Bittinger, F
    Engelbach, M
    Beyer, J
    [J]. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 1998, 106 (02) : 123 - 129
  • [6] Meier R F, 1998, Saudi J Gastroenterol, V4, P147
  • [7] Clinical utility of lanreotide Autogel® in gastroenteropancreatic neuroendocrine tumors
    Paragliola, Rosa Maria
    Prete, Alessandro
    Papi, Giampaolo
    Torino, Francesco
    Corsello, Andrea
    Pontecorvi, Alfredo
    Corsello, Salvatore Maria
    [J]. DRUG DESIGN DEVELOPMENT AND THERAPY, 2016, 10 : 3459 - 3470
  • [8] Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors
    Pokuri, Venkata K.
    Fong, Mei Ka
    Iyer, Renuka
    [J]. CURRENT ONCOLOGY REPORTS, 2016, 18 (01) : 1 - 9
  • [9] Management of gastric and duodenal neuroendocrine tumors
    Sato, Yuichi
    Hashimoto, Satoru
    Mizuno, Ken-ichi
    Takeuchi, Manabu
    Terai, Shuji
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (30) : 6817 - 6828
  • [10] Syro LV, 2012, CLINICS, V67, P43